Fetal fibronectin as a biomarker of preterm labor: A review of the literature and advances in its clinical use

Biomarkers in Medicine

Volumn 8, Issue 4, 2014, Pages 471-484

  Foster, Claire ^a   Shennan, Andrew H ^b  

^a MERCY HOSPITAL FOR WOMEN   (Australia)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

biomarkers; cervical cerclage; fetal fibronectin; multiple gestations; prediction; preterm birth; quantitative fetal fibronectin

Indexed keywords

BIOLOGICAL MARKER; FETAL FIBRONECTIN; FIBRONECTIN; UNCLASSIFIED DRUG;

CERVICAL LENGTH MEASUREMENT; CLINICAL DECISION MAKING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GESTATIONAL AGE; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; INCIDENCE; NEWBORN MORBIDITY; NEWBORN MORTALITY; OUTCOME ASSESSMENT; PATIENT CARE; PREDICTIVE VALUE; PREMATURE LABOR; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REASSURANCE; REVIEW; RISK ASSESSMENT; SYMPTOMATOLOGY; TREATMENT INDICATION; UTERINE CERVIX CERCLAGE; VAGINAL SECRETION; METABOLISM; MULTIPLE PREGNANCY; OBSTETRIC LABOR, PREMATURE; PREGNANCY; PREMATURITY;

BIOLOGICAL MARKERS; CERCLAGE, CERVICAL; FEMALE; FIBRONECTINS; HUMANS; MULTIPLE BIRTH OFFSPRING; OBSTETRIC LABOR, PREMATURE; PREGNANCY; PREMATURE BIRTH;

EID: 84899844929     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.14.28     Document Type: Review

References (74)

1. Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet 371(9606), 75-84 (2008).
2. Blencowe H, Cousens S, Oestergaard MZ et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet 379(9832), 2162-2172 (2012).
3. WHO: recommended definitions, terminology and format for statistical tables related to the perinatal period and use of a new certificate for cause of perinatal deaths. Modifications recommended by FIGO as amended October 14, 1976. Acta Obstet. Gynecol. Scand. 56(3), 247-253 (1977).
4. Berghella V, Hayes E, Visintine J, Baxter JK. Fetal fibronectin testing for reducing the risk of preterm birth. Cochrane Database Syst. Rev. 4, CD006843 (2008).
5. Langhoff-Roos J, Kesmodel U, Jacobsson B, Rasmussen S, Vogel I. Spontaneous preterm delivery in primiparous women at low risk in Denmark: population based study. BMJ 332(7547), 937-939 (2006).
6. Slattery MM, Morrison JJ. Preterm delivery. Lancet 360(9344), 1489-1497 (2002).
7. Morken NH. Preterm birth: new data on a global health priority. Lancet 379(9832), 2128-2130 (2012).
8. March of Dimes, Perinatal Data Center. Special care nursery admissions (2011). www.marchofdimes.com
9. Marlow N, Wolke D, Bracewell MA, Samara M; EPICure Study Group. Neurologic and developmental disability at six years of age after extremely preterm birth. N. Engl. J. Med. 352(1), 9-19 (2005).
10. Mangham LJ, Petrou S, Doyle LW, Draper ES, Marlow N. The cost of preterm birth throughout childhood in England and Wales. Pediatrics 123(2), e312-e327 (2009).
11. Petrou S. The economic consequences of preterm birth during the first 10 years of life. BJOG 112(Suppl. 1), 10-15 (2005).
12. Wood NS, Marlow N, Costeloe K, Gibson AT, Wilkinson AR. Neurologic and developmental disability after extremely preterm birth. EPICure Study Group. N. Engl. J. Med. 343(6), 378-384 (2000).
13. Lockwood CJ, Kuczynski E. Risk stratification and pathological mechanisms in preterm delivery. Paediatr. Perinat. Epidemiol. 15(Suppl. 2), 78-89 (2001).
14. Creasy RK, Gummer BA, Liggins GC. System for predicting spontaneous preterm birth. Obstet. Gynecol. 55(6), 692-695 (1980).
15. Honest H, Bachmann LM, Sundaram R, Gupta JK, Kleijnen J, Khan KS. The accuracy of risk scores in predicting preterm birth - a systematic review. J. Obstet. Gynaecol. 24(4), 343-359 (2004).
16. Ness A, Visintine J, Ricci E, Berghella V. Does knowledge of cervical length and fetal fibronectin affect management of women with threatened preterm labor? A randomized trial. Am. J. Obstet. Gynecol. 197(4), 426.e421-426.e427 (2007).
17. Matsuura H, Hakomori S. The oncofetal domain of fibronectin defined by monoclonal antibody FDC-6: its presence in fibronectins from fetal and tumor tissues and its absence in those from normal adult tissues and plasma. Proc. Natl Acad. Sci. USA 82(19), 6517-6521 (1985).
18. Dutta D, Norman JE. The efficacy of fetal fibronectin testing in minimising hospital admissions, length of hospital stay and cost savings in women presenting with symptoms of preterm labour. J. Obstet. Gynecol. 30(8), 768-773 (2010).
19. Lockwood CJ, Senyei AE, Dische MR et al. Fetal fibronectin in cervical and vaginal secretions as a predictor of preterm delivery. N. Engl. J. Med. 325(10), 669-674 (1991).
20. Honest H, Bachmann LM, Gupta JK, Kleijnen J, Khan KS. Accuracy of cervicovaginal fetal fibronectin test in predicting risk of spontaneous preterm birth: systematic review. BMJ 325(7359), 301 (2002).
21. Bittar RE, Yamasaki AA, Sasaki S, Zugaib M. Cervical fetal fibronectin in patients at increased risk for preterm delivery. Am. J. Obstet. Gynecol. 175(1), 178-181 (1996).
22. Goepfert AR, Goldenberg RL, Mercer B et al. The Preterm Prediction Study: quantitative fetal fibronectin values and the prediction of spontaneous preterm birth. Am. J. Obstet. Gynecol. 183(6), 1480-1483 (2000).
23. Iams JD, Casal D, McGregor JA et al. Fetal fibronectin improves the accuracy of diagnosis of preterm labor. Am. J. Obstet. Gynecol. 173(1), 141-145 (1995).
24. Riboni F, Vitulo A, Dell'avanzo M, Plebani M, Battagliarin G, Paternoster D. Biochemical markers predicting pre-term delivery in symptomatic patients: phosphorylated insulin-like growth factor binding protein-1 and fetal fibronectin. Arch. Obstet. Gynecol. 284(6), 1325-1329 (2011).
25. Bartnicki J, Casal D, Kreaden US, Saling E, Vetter K. Fetal fibronectin in vaginal specimens predicts preterm delivery and very-low-birth-weight infants. Am. J. Obstet. Gynecol. 174(3), 971-974 (1996).
26. Sunagawa S, Takagi K, Ono K, Miyachi K, Kikuchi A. Comparison of biochemical markers and cervical length for predicting preterm delivery. J. Obstet. Gynecol. Res. 34(5), 812-819 (2008).
27. Gomez R, Romero R, Medina L et al. Cervicovaginal fibronectin improves the prediction of preterm delivery based on sonographic cervical length in patients with preterm uterine contractions and intact membranes. Am. J. Obstet. Gynecol. 192(2), 350-359 (2005).
28. Peaceman AM, Andrews WW, Thorp JM et al. Fetal fibronectin as a predictor of preterm birth in patients with symptoms: a multicenter trial. Am. J. Obstet. Gynecol. 177(1), 13-18 (1997).
29. Inglis SR, Jeremias J, Kuno K et al. Detection of tumor necrosis factor-Alpha, interleukin-6, and fetal fibronectin in the lower genital tract during pregnancy: relation to outcome. Am. J. Obstet. Gynecol. 171(1), 5-10 (1994).
30. Morrison JC, Allbert JR, McLaughlin BN, Whitworth NS, Roberts WE, Martin RW. Oncofetal fibronectin in patients with false labor as a predictor of preterm delivery. Am. J. Obstet. Gynecol. 168(2), 538-542 (1993).
31. Yoneda S, Sakai M, Sasaki Y, Shiozaki A, Hidaka T, Saito S. Interleukin-8 and glucose in amniotic fluid, fetal fibronectin in vaginal secretions and preterm labor index based on clinical variables are optimal predictive markers for preterm delivery in patients with intact membranes. J. Obstet. Gynecol. Res. 33(1), 38-44 (2007).
32. Sakai M, Sasaki Y, Yamagishi N, Tanebe K, Yoneda S, Saito S. The preterm labor index and fetal fibronectin for prediction of preterm delivery with intact membranes. Obstet. Gynecol. 101(1), 123-128 (2003).
33. Smith V, Devane D, Begley CM, Clarke M, Higgins S. A systematic review and quality assessment of systematic reviews of fetal fibronectin and transvaginal length for predicting preterm birth. Eur. J. Obstet. Gynecol. Reprod. Biol. 133(2), 134-142 (2007).
34. Revah A, Hannah ME, Sue-A-Quan AK. Fetal fibronectin as a predictor of preterm birth: an overview. Am. J. Perinatol. 15(11), 613-621 (1998).
35. Leitich H, Egarter C, Kaider A, Hohlagschwandtner M, Berghammer P, Husslein P. Cervicovaginal fetal fibronectin as a marker for preterm delivery: a meta-Analysis. Am. J. Obstet. Gynecol. 180(5), 1169-1176 (1999).
36. Faron G, Boulvain M, Irion O, Bernard PM, Fraser WD. Prediction of preterm delivery by fetal fibronectin: a meta-Analysis. Obstet. Gynecol. 92(1), 153-158 (1998).
37. Chien PF, Khan KS, Ogston S, Owen P. The diagnostic accuracy of cervico-vaginal fetal fibronectin in predicting preterm delivery: an overview. Br. J. Obstet. Gynaecol. 104(4), 436-444 (1997).
38. Grobman WA, Welshman EE, Calhoun EA. Does fetal fibronectin use in the diagnosis of preterm labor affect physician behavior and health care costs? A randomized trial. Am. J. Obstet. Gynecol. 191(1), 235-240 (2004).
39. Giles W, Bisits A, Knox M, Madsen G, Smith R. The effect of fetal fibronectin testing on admissions to a tertiary maternal-fetal medicine unit and cost savings. Am. J. Obstet. Gynecol. 182(2), 439-442 (2000).
40. van Baaren GJ, Vis JY, Grobman WA, Bossuyt PM, Opmeer BC, Mol BW. Cost-effectiveness analysis of cervical length measurement and fibronectin testing in women with threatened preterm labor. Am. J. Obstet. Gynecol. 209(5), 436.e1-436.e8 (2013).
41. Goldenberg RL, Mercer BM, Meis PJ, Copper RL, Das A, Mcnellis D. The preterm prediction study: fetal fibronectin testing and spontaneous preterm birth. NICHD Maternal Fetal Medicine Units Network. Obstet. Gynecol. 87(5 Pt 1), 643-648 (1996).
42. Goldenberg RL, Iams JD, Mercer BM et al. The preterm prediction study: the value of new vs standard risk factors in predicting early and all spontaneous preterm births. NICHD MFMU Network. Am. J. Public Health 88(2), 233-238 (1998).
43. Hellemans P, Gerris J, Verdonk P. Fetal fibronectin detection for prediction of preterm birth in low risk women. Br. J. Obstet. Gynaecol. 102(3), 207-212 (1995).
44. Nageotte MP, Casal D, Senyei AE. Fetal fibronectin in patients at increased risk for premature birth. Am. J. Obstet. Gynecol. 170(1 Pt 1), 20-25 (1994).
45. Duhig KE, Chandiramani M, Seed PT, Briley AL, Kenyon AP, Shennan AH. Fetal fibronectin as a predictor of spontaneous preterm labour in asymptomatic women with a cervical cerclage. BJOG 116(6), 799-803 (2009).
46. Bastek JA, Hirshberg A, Chandrasekaran S et al. Biomarkers and cervical length to predict spontaneous preterm birth in asymptomatic high-risk women. Obstet. Gynecol. 122(2 Pt 1), 283-289 (2013).
47. Bolt LA, Chandiramani M, De Greeff A, Seed P, Shennan AH. Does fetal fibronectin testing change patient management in women at risk of preterm labour? Eur.J. Obstet. Gynecol. Reprod. Biol. 146(2), 180-183 (2009).
48. Shennan A, Jones G, Hawken J et al. Fetal fibronectin test predicts delivery before 30 weeks of gestation in high risk women, but increases anxiety. BJOG 112(3), 293-298 (2005).
49. Lowe MP, Zimmerman B, Hansen W. Prospective randomized controlled trial of fetal fibronectin on preterm labor management in a tertiary care center. Am. J. Obstet. Gynecol. 190(2), 358-362 (2004).
50. Kurtzman J, Chandiramani M, Briley A, Poston L, Das A, Shennan A. Quantitative fetal fibronectin screening in asymptomatic high-risk patients and the spectrum of risk for recurrent preterm delivery. Am. J. Obstet. Gynecol. 200(3), 263.e1-263.e6 (2009).
51. Lu GC, Goldenberg RL, Cliver SP, Kreaden US, Andrews WW. Vaginal fetal fibronectin levels and spontaneous preterm birth in symptomatic women. Obstet. Gynecol. 97(2), 225-228 (2001).
52. Goldenberg RL, Mercer BM, Iams JD et al. The preterm prediction study: patterns of cervicovaginal fetal fibronectin as predictors of spontaneous preterm delivery. Am. J. Obstet. Gynecol. 177(1), 8-12 (1997).
53. Abbott DS, Radford SK, Seed PT, Tribe RM, Shennan AH. Evaluation of a quantitative fetal fibronectin test for spontaneous preterm birth in symptomatic women. Am. J. Obstet. Gynecol. 208(2), 122.e1-122.e6 (2013).
54. Crane JM, Hutchens D. Transvaginal sonographic measurement of cervical length to predict preterm birth in asymptomatic women at increased risk: a systematic review. Ultrasound Obstet. Gynecol. 31(5), 579-587 (2008).
55. Fox NS, Jean-Pierre C, Predanic M, Chasen ST. Short cervix: is a follow-up measurement useful? Ultrasound Obstet. Gynecol. 29(1), 44-46 (2007).
56. To MS, Skentou CA, Royston P, Yu CK, Nicolaides KH. Prediction of patient-specific risk of early preterm delivery using maternal history and sonographic measurement of cervical length: a population-based prospective study. Ultrasound Obstet. Gynecol. 27(4), 362-367 (2006).
57. Chao AS, Chao A, Hsieh PC. Ultrasound assessment of cervical length in pregnancy. Taiwan. J. Obstet. Gynecol. 47(3), 291-295 (2008).
58. Kagan KO, To M, Tsoi E, Nicolaides KH. Preterm birth: the value of sonographic measurement of cervical length. BJOG 113(Suppl. 3), 52-56 (2006).
59. Bolt LA, Chandiramani M, De Greeff A, Seed PT, Kurtzman J, Shennan AH. The value of combined cervical length measurement and fetal fibronectin testing to predict spontaneous preterm birth in asymptomatic high-risk women. J. Matern. Fetal Neonatal Med. 24(7), 928-932 (2011).
60. DeFranco EA, Lewis DF, Odibo AO. Improving the screening accuracy for preterm labor: is the combination of fetal fibronectin and cervical length in symptomatic patients a useful predictor of preterm birth? A systematic review. Am. J. Obstet. Gynecol. 208(3), 233.e1-233.e6 (2013).
61. Yeast JD, Lu G. Biochemical markers for the prediction of preterm delivery. Clin. Perinatol. 34(4), 573-586, vi (2007).
62. Goldenberg RL, Iams JD, Mercer BM et al. The Preterm Prediction Study: toward a multiple-marker test for spontaneous preterm birth. Am. J. Obstet. Gynecol. 185(3), 643-651 (2001).
63. Khambay H, Bolt LA, Chandiramani M, De Greeff A, Filmer JE, Shennan AH. The Actim Partus test to predict pre-term birth in asymptomatic high-risk women. J. Obstet. Gynecol. 32(2), 132-134 (2012).
64. Nikolova T, Bayev O, Nikolova N, Di Renzo GC. Evaluation of a novel placental alpha microglobulin-1 (PAMG-1) test to predict spontaneous preterm delivery. J. Perinat. Med. 13, 1-5 (2013).
65. Lukes AS, Thorp JM Jr, Eucker B, Pahel-Short L. Predictors of positivity for fetal fibronectin in patients with symptoms of preterm labor. Am. J. Obstet. Gynecol. 176(3), 639-641 (1997).
66. Martin JA, Hamilton BE, Ventura SJ et al. Births: final data for 2009. Natl Vital Stat. Rep. 60(1), 1-70 (2011).
67. Reynolds MA, Schieve LA, Martin JA, Jeng G, Macaluso M. Trends in multiple births conceived using assisted reproductive technology, United States, 1997-2000. Pediatrics 111(5 Pt 2), 1159-1162 (2003).
68. Zork N, Biggio J, Tita A, Rouse D, Gyamfi-Bannerman C. Decreasing prematurity in twin gestations: predicaments and possibilities. Obstet. Gynecol. 122(2 Pt 1), 375-379 (2013).
69. Conde-Agudelo A, Romero R. Cervicovaginal fetal fibronectin for the prediction of spontaneous preterm birth in multiple pregnancies: a systematic review and metaanalysis. J. Matern. Fetal Neonatal Med. 23(12), 1365-1376 (2010).
70. Fox NS, Saltzman DH, Klauser CK, Peress D, Gutierrez CV, Rebarber A. Prediction of spontaneous preterm birth in asymptomatic twin pregnancies with the use of combined fetal fibronectin and cervical length. Am. J. Obstet. Gynecol. 201(3), 313.e1-313.e5 (2009).
71. Roman AS, Pessel C, Fox N, Klauser CK, Saltzman D, Rebarber A. Vaginal fetal fibronectin as a predictor of spontaneous preterm delivery in triplet gestations. J. Matern. Fetal Neonatal Med. 25(10), 1921-1923 (2012).
72. Tolino A, Ronsini S, Zullo F, Pellicano M, Regine V, Nappi C. Fetal fibronectin as a screening test for premature delivery in multiple pregnancies. Int. J. Gynaecol. Obstet. 52(1), 3-7 (1996).
73. Roman AS, Rebarber A, Sfakianaki AK et al. Vaginal fetal fibronectin as a predictor of spontaneous preterm delivery in the patient with cervical cerclage. Am. J. Obstet. Gynecol. 189(5), 1368-1373 (2003).
74. Benson JE, Landy HJ, Ghidini A, Drassinower D, Poggi SH. Fetal fibronectin for evaluation of preterm labor in the setting of cervical cerclage. J. Matern. Fetal Neonatal Med. 25(11), 2330-2332 (2012).